Advertisement
Chinese billionaire behind Hansoh Pharmaceutical enriched as Hang Seng Index review fuels rally among new elite members
- Chairwoman and CEO Zhong Huijuan and her Cambridge-trained daughter control 66 per cent of the Shanghai-based pharma group
- Three other new index members – Baidu, Chow Tai Fook Jewellery and China Shenhua Energy – will also join from September 5
3-MIN READ3-MIN

Hansoh Pharmaceuticals jumped as much as 7.2 per cent in Hong Kong after the stock was picked with three others to join the benchmark Hang Seng Index from next month, thrusting China’s sixth richest woman into the limelight.
The stock traded as high as HK$16.62 before settling 3.2 per cent higher at HK$16 when trading closed on Monday, leading gains among new index members after the latest quarterly review. The increase added almost HK$3 billion (US$377 million) of market value to the group.
The Shanghai-based group has a market capitalisation of HK$94.8 billion, having lost 16 per cent or HK$17.8 billion this year. The stock crashed 49 per cent in 2021, erasing HK$110 billion of value.
Select Voice
Select Speed
1x
AI-generated voice